Supernus Pharmaceuticals (NASDAQ:SUPN) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a research note released on Wednesday. Separately, Piper Sandler lifted their target price on shares of Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an overweight rating in a report on Thursday, November 9th. […]

Leave a Reply

Your email address will not be published.

Previous post Albert Soleiman Buys 332 Shares of CMC Markets plc (LON:CMCX) Stock
Next post Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Reiterated by Cantor Fitzgerald